{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T19:01:25Z","timestamp":1772046085324,"version":"3.50.1"},"reference-count":34,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Understanding patient preferences concerning the use of biologics for psoriasis treatment can support proper treatment selection to satisfy their needs. In Japan, limited studies have reported psoriasis patients' preferences for the use of biologics, and many of those focused on the improvement of skin symptoms. The present study was conducted as a web\u2010based questionnaire survey using the discrete choice experiment approach to investigate the preferences of psoriasis patients for the use of biologics, as well as to describe social and clinical factors that influence these preferences. The following attributes were selected for the discrete choice experiment: efficacy at 1\u00a0year, risk of serious infections requiring hospitalization, incidence of injection site reactions, administration route and visits, co\u2010payment, indications, and efficacy on skin symptoms and other manifestations (the last two have not been evaluated in previous studies). Data were collected from October 4 to October 8, 2021. An analysis of data from 357 psoriasis patients indicated that the most preferred attributes for biologics selection were administration route and visits, followed by the risk of serious infections requiring hospitalization. Some differences were observed among specific subgroups. This study demonstrated that patients with psoriasis prefer biologics with a less frequent administration route and visit schedule and a lower risk of serious infections requiring hospitalization, which contrasts with the results obtained in previous studies where the highest importance was placed on drug effectiveness. These results may reflect the personal and social impact of the coronavirus disease outbreak at the time of the survey. The results of this study might help physicians properly select biologics that satisfy psoriasis patients' needs, leading to better treatment adherence.<\/jats:p>","DOI":"10.1111\/1346-8138.16703","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T08:24:40Z","timestamp":1673425480000},"page":"596-607","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Psoriasis patient preferences for the use of biologics during the coronavirus era"],"prefix":"10.1111","volume":"50","author":[{"given":"Yayoi","family":"Tada","sequence":"first","affiliation":[{"name":"Department of Dermatology Teikyo University School of Medicine  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asako","family":"Itakura","sequence":"additional","affiliation":[{"name":"Novartis Pharma K. K.  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumiko","family":"Hosono","sequence":"additional","affiliation":[{"name":"Novartis Pharma K. K.  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taisuke","family":"Kawamura","sequence":"additional","affiliation":[{"name":"Novartis Pharma K. K.  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,1,11]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0804595"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-4-35"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.033217"},{"key":"e_1_2_9_5_1","unstructured":"World Health Organization.Global Report on Psoriasis 2016. Published 2016 [cited 2022 April 26]. Available from:http:\/\/jpa1029.com\/GlobalReportOnPsoriasis\/GlobalReportOnPsoriasis.pdf"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006450"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15803"},{"key":"e_1_2_9_8_1","first-page":"2675","article-title":"Guidelines for the treatment of psoriatic arthritis","volume":"129","author":"Asahina A","year":"2019","journal-title":"J Dermatol"},{"key":"e_1_2_9_9_1","first-page":"2211","article-title":"Guidelines for the treatment of pustular psoriasis (generalized type) (2014)","volume":"125","author":"Terui T","year":"2015","journal-title":"J Dermatol"},{"key":"e_1_2_9_10_1","first-page":"1935","article-title":"Questionnaire survey of perceived satisfaction with treatment of patients with psoriasis","volume":"23","author":"Torii H","year":"2013","journal-title":"Jpn J Dermatol"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1920898"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12372"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-016-1321-7"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15196"},{"key":"e_1_2_9_15_1","unstructured":"Ministry of Health Labour and Welfare.Patient's behavior survey. 2020. Published 2021 [cited 2022 April 26]. Available from:https:\/\/www.mhlw.go.jp\/toukei\/saikin\/hw\/jyuryo\/20\/dl\/kekka\u2010gaiyo.pdf"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1304"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-018-0104-1"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14870"},{"key":"e_1_2_9_19_1","unstructured":"World Health Organization.Coronavirus disease (COVID\u201019) pandemic. [cited 2022 June 1]. Available from:https:\/\/www.who.int\/emergencies\/diseases\/novel\u2010coronavirus\u20102019"},{"key":"e_1_2_9_20_1","unstructured":"Cabinet Secretariat.Report on the implementation of declaration of a State of Emergency. Published 2021 [cited 2022 June 1]. Available from:https:\/\/corona.go.jp\/news\/pdf\/houkoku_r031008.pdf"},{"key":"e_1_2_9_21_1","volume-title":"Getting started with conjoint analysis: strategies for product design and pricing research","author":"Orme BK","year":"2006"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12895-020-00099-7"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.08.026"},{"key":"e_1_2_9_24_1","unstructured":"The Japanese Dermatological Association.Institutions approved for the use of biologics for psoriasis. Published 2022 [cited 2022 Nov 9]. Available from:https:\/\/www.dermatol.or.jp\/modules\/biologics\/index.php?content_id=4"},{"key":"e_1_2_9_25_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0129120","article-title":"Patient preferences for treatment of psoriasis with biologicals: a discrete choice experiment","volume":"10","author":"Christian K","year":"2015","journal-title":"PLoS One"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-017-0205-2"},{"key":"e_1_2_9_27_1","unstructured":"Ministry of Health Labour and Welfare.Annual health labour and welfare report 2021. Published 2021 [cited 2022 April 26]. Available from:https:\/\/www.mhlw.go.jp\/content\/000810636.pdf"},{"key":"e_1_2_9_28_1","unstructured":"Ministry of Health Labour and Welfare.Domestic outbreaks etc.Published 2022 [cited 2022 April 26]. Available from:https:\/\/www.mhlw.go.jp\/stf\/covid\u201019\/kokunainohasseijoukyou.html"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.2169\/naika.107.110"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12596"},{"key":"e_1_2_9_31_1","unstructured":"National Institute of Infectious Diseases.About the Covid\u201019 vaccine (as of October 8 2021). Published 2021 [cited 2022 April 26]. Available from:https:\/\/www.niid.go.jp\/niid\/images\/epi\/corona\/60\/covid19_vaccine_202110008.pdf"},{"key":"e_1_2_9_32_1","unstructured":"Prime Minister of Japan and His Cabinet.COVID\u201019 Vaccines Published 2022 [cited 26 April 2022]. Available from URL:https:\/\/www.kantei.go.jp\/jp\/headline\/kansensho\/vaccine.html"},{"key":"e_1_2_9_33_1","unstructured":"Japan Medical Journal.Psoriatic arthritis is not rare. Published 2016 [cited 2022 May 16]. Available from:https:\/\/www.jmedj.co.jp\/journal\/paper\/detail.php?id=2130"},{"key":"e_1_2_9_34_1","unstructured":"MIX Inc.90% of psoriasis patients are unaware of the association with joint symptoms. Only 40% of patients experience symptoms. Lack of information from dermatologists?Published 2013 [cited 2022 May 16]. Available from:https:\/\/www.mixonline.jp\/tabid55.html?artid=45059"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00695-0"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.16703","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1346-8138.16703","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.16703","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T12:30:56Z","timestamp":1692707456000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.16703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,11]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1111\/1346-8138.16703"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.16703","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,11]]},"assertion":[{"value":"2022-09-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}